NO20042256L - Rasemisk fri tamsulosinbase samt fremgangsmater ved fremstilling derav - Google Patents

Rasemisk fri tamsulosinbase samt fremgangsmater ved fremstilling derav

Info

Publication number
NO20042256L
NO20042256L NO20042256A NO20042256A NO20042256L NO 20042256 L NO20042256 L NO 20042256L NO 20042256 A NO20042256 A NO 20042256A NO 20042256 A NO20042256 A NO 20042256A NO 20042256 L NO20042256 L NO 20042256L
Authority
NO
Norway
Prior art keywords
preparation
methods
racemic free
tamsulosin base
tamsulosin
Prior art date
Application number
NO20042256A
Other languages
English (en)
Norwegian (no)
Inventor
Hans Jan Hoorn
Theodorus Hendricus Antonius Peters
Jaroslav Pis
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20042256L publication Critical patent/NO20042256L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20042256A 2001-10-31 2004-06-01 Rasemisk fri tamsulosinbase samt fremgangsmater ved fremstilling derav NO20042256L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33081701P 2001-10-31 2001-10-31
US10/208,009 US6835853B2 (en) 2001-10-31 2002-07-31 Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith
PCT/NL2002/000660 WO2003037851A1 (en) 2001-10-31 2002-10-17 Racemic tamsulosin free base and methods of making the same

Publications (1)

Publication Number Publication Date
NO20042256L true NO20042256L (no) 2004-07-28

Family

ID=26902810

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042256A NO20042256L (no) 2001-10-31 2004-06-01 Rasemisk fri tamsulosinbase samt fremgangsmater ved fremstilling derav

Country Status (17)

Country Link
US (2) US6835853B2 (cs)
EP (2) EP1444198A1 (cs)
CN (2) CN100343227C (cs)
AT (2) ATE417822T1 (cs)
AU (2) AU2002330774B9 (cs)
CA (2) CA2464648C (cs)
CH (3) CH697164A5 (cs)
CZ (2) CZ13392U1 (cs)
DE (3) DE60230438D1 (cs)
DK (2) DK200200339U3 (cs)
FI (2) FI5957U1 (cs)
FR (2) FR2832146B1 (cs)
IL (2) IL161449A0 (cs)
IS (2) IS6603A (cs)
NL (2) NL1021671C2 (cs)
NO (1) NO20042256L (cs)
WO (2) WO2003037850A1 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200699B1 (es) * 2002-07-12 2005-10-01 Ragactives, S.L Procedimiento para la separacion de r(-) y s(+)-5-(2-((2-(etoxifenoxi)etil)amino)propil-2-metoxibenceno-sulfonamida.
USH2154H1 (en) * 2003-10-08 2006-04-04 Farmak, A.S. Process for preparing R- and S-isomers of (R)-5-(2-( (2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
SI21656A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska družba d.d. Priprava (R)-5-(2-(2-(2-etoksifenoksi) etilamino)-1-propil)-2-metoksibenzensulfonamida hidroklorida z visoko kemijsko čistoto
SI21702A (en) * 2004-01-29 2005-08-31 Lek Farmacevtska Druzba Dd Preparation of amorphous form of tamsulosin
US8436029B2 (en) * 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
CN100545148C (zh) 2004-08-16 2009-09-30 神隆新加坡私人有限公司 一种抗良性前列腺肥大药物坦索罗辛之合成方法
US7238839B2 (en) 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
PT103216B (pt) 2004-12-06 2010-05-19 Hovione Farmaciencia S A Preparação de tamsulosin
WO2006117662A2 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Polymorphic forms of (r)-(-)-tamsulosin
US20090137844A1 (en) * 2005-06-15 2009-05-28 Fermion Oy Crystallization process
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20080312328A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched tamsulosin
DE102008002409A1 (de) * 2008-06-13 2009-12-17 Evonik Goldschmidt Gmbh Enzymatische Synthese von Sphingolipiden
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
EP2338876A1 (en) 2009-12-22 2011-06-29 LEK Pharmaceuticals d.d. Tamsulosin adipate for pharmaceutical use
KR101525493B1 (ko) * 2013-01-02 2015-06-03 보령제약 주식회사 고순도 탐술로신 또는 이의 염 제조방법
CN104926699B (zh) * 2015-07-02 2018-09-25 成都丽凯手性技术有限公司 一种高光学纯度盐酸坦索罗辛的制备方法
CN106631918B (zh) * 2016-10-13 2018-07-13 深圳万和制药有限公司 拆分坦索罗辛对映异构体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH383998A (de) * 1959-08-05 1964-11-15 Ciba Geigy Verfahren zur Herstellung neuer sekundärer Amine
US3412154A (en) * 1964-08-12 1968-11-19 Parke Davis & Co Amino-substituted phenone compounds
CA1147342A (en) 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPH066565B2 (ja) 1986-07-21 1994-01-26 山之内製薬株式会社 光学活性なベンゼンスルホンアミド誘導体の製造法
ES2098069T3 (es) * 1993-02-23 1997-04-16 Hoechst Ag Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y su utilizacion como agentes farmaceuticos.
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives

Also Published As

Publication number Publication date
CA2464917A1 (en) 2003-05-08
US6835853B2 (en) 2004-12-28
US20050096394A1 (en) 2005-05-05
AU2002330774B9 (en) 2010-01-07
EP1444199B1 (en) 2008-12-17
US20030109752A1 (en) 2003-06-12
CN100579958C (zh) 2010-01-13
FR2832146B1 (fr) 2006-05-26
CZ13580U1 (cs) 2003-08-18
AU2002330776B2 (en) 2009-03-12
EP1444198A1 (en) 2004-08-11
CN1578762A (zh) 2005-02-09
FR2832147A1 (fr) 2003-05-16
DE60230438D1 (de) 2009-01-29
FIU20020421U0 (fi) 2002-10-23
FR2832147B1 (fr) 2006-06-02
DE20216779U1 (de) 2003-09-04
DK200200338U1 (da) 2003-01-31
FR2832146A1 (fr) 2003-05-16
FI5816U1 (fi) 2003-06-06
DK200200339U3 (da) 2003-06-13
WO2003037851A1 (en) 2003-05-08
FI5957U1 (fi) 2003-09-30
CH697164A5 (de) 2008-05-30
IL161490A0 (en) 2004-09-27
CZ13392U1 (cs) 2003-06-24
IL161449A0 (en) 2004-09-27
CH696665A5 (de) 2007-09-14
AU2002330774B2 (en) 2009-06-04
IS6602A (is) 2003-05-02
EP1444199A1 (en) 2004-08-11
CN100343227C (zh) 2007-10-17
CA2464648A1 (en) 2003-05-08
CN1578761A (zh) 2005-02-09
NL1021671C2 (nl) 2003-05-15
CA2464648C (en) 2009-07-14
US6965051B2 (en) 2005-11-15
WO2003037850A1 (en) 2003-05-08
DE20216835U1 (de) 2003-09-25
DK200200339U1 (da) 2003-01-31
DK200200338U3 (da) 2003-07-11
CA2464917C (en) 2009-06-02
IS6603A (is) 2003-05-02
CH697034A5 (de) 2008-03-31
FIU20020420U0 (fi) 2002-10-23
ATE417822T1 (de) 2009-01-15
AT6687U1 (de) 2004-02-25
NL1021678C2 (nl) 2003-05-15

Similar Documents

Publication Publication Date Title
NO20042256L (no) Rasemisk fri tamsulosinbase samt fremgangsmater ved fremstilling derav
ITMI20022233A1 (it) Apparecchiatura di ricezione-trasmissione e procedimento
IS7125A (is) Ný sýklóhexýl súlfon
EP1578771A4 (en) REMODELING AND GLYCOKON JUGATION OF PEPTIDES
DK1443917T3 (da) Tamsulosintabletter
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
DE60232994D1 (de) Inhibitoren von mitotischem kinesin
DE60204695D1 (de) Entsafter
SG122743A1 (en) Microelectronic devices and methods of manufacture
NO20040353L (no) Ny terapeutsk metode
NO20035121D0 (no) Ny anvendelse
EP1293204A4 (en) UREA-CONTAINING GEL COMPOSITION
DE60125981D1 (de) Amlodipin in form der freien base
ITMI20011532A0 (it) Cosmetico solido
DE60239866D1 (de) Fischer-tropsch-verfahren
ATE319346T1 (de) Enthaarungswachsapplikator
DE60309255D1 (de) Abbildung und Entnahme von Gel
DE60126734D1 (de) Superiostealer Knochenanker
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
IL159820A0 (en) Denture base and method of preparing it and instrument used therefor
NO20033919D0 (no) Ny anvendelse
NO20011176D0 (no) FremgangsmÕte og anordning ved mær
EP1406921A4 (en) HYPOGLYCAEMIC PEPTIDES AND METHOD FOR USE THEREOF
DK1366039T3 (da) Piperazinylcarbonylquinoliner og -isoquinoliner
HU0102942D0 (en) Device for base of polygon crossing piece

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application